BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 27777009)

  • 1. Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit.
    Wang M; Xu S; Wu C; Liu X; Tao H; Huang Y; Liu Y; Zheng P; Zhu W
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5450-5454. PubMed ID: 27777009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.
    Wang M; Xu S; Lei H; Wang C; Xiao Z; Jia S; Zhi J; Zheng P; Zhu W
    Bioorg Med Chem; 2017 Oct; 25(20):5754-5763. PubMed ID: 28927801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit.
    Wu C; Wang M; Tang Q; Luo R; Chen L; Zheng P; Zhu W
    Molecules; 2015 Oct; 20(10):19361-71. PubMed ID: 26512636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, activity and docking studies of phenylpyrimidine-carboxamide Sorafenib derivatives.
    Wang W; Wu C; Wang J; Luo R; Wang C; Liu X; Li J; Zhu W; Zheng P
    Bioorg Med Chem; 2016 Dec; 24(23):6166-6173. PubMed ID: 28340913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, Biological Evaluation and Docking Studies of Sorafenib Derivatives N-(3-fluoro-4-(pyridin-4-yloxy)phenyl)-4(5)-phenylpicolinamides.
    Wang M; Wu C; Xu S; Zhu Y; Li W; Zheng P; Zhu W
    Med Chem; 2017; 13(2):176-185. PubMed ID: 27855595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological activities of sorafenib derivatives as antitumor agents.
    Yao J; He Z; Chen J; Sun W; Fang H; Xu W
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6549-53. PubMed ID: 23021967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and in vitro antitumor activities of novel benzyl urea analogues of sorafenib.
    Lu CS; Tang K; Li Y; Jin B; Yin DL; Ma C; Chen XG; Huang HH
    Yao Xue Xue Bao; 2013 May; 48(5):709-17. PubMed ID: 23888694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Design, synthesis and antitumor activity of sorafenib analogues containing 2-picolinylhydrazide moiety].
    Qin AF; Li Y; Song HR; Chen XG; Jin XF; Wang K; Zhang LJ; Huo LC; Feng ZQ
    Yao Xue Xue Bao; 2012 Dec; 47(12):1623-9. PubMed ID: 23460968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
    Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
    Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
    El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
    Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Synthesis and in vitro cytotoxic activities of sorafenib derivatives].
    Wang K; Li Y; Zhang LJ; Yang HZ; Chen XG; Feng ZQ
    Yao Xue Xue Bao; 2014 May; 49(5):639-43. PubMed ID: 25151734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
    El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
    Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.
    Zeidan MA; Mostafa AS; Gomaa RM; Abou-Zeid LA; El-Mesery M; El-Sayed MA; Selim KB
    Eur J Med Chem; 2019 Apr; 168():315-329. PubMed ID: 30826508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation.
    Ahmed MF; Santali EY; El-Haggar R
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):307-318. PubMed ID: 33349069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
    Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
    Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.